{"entity":{"id":"nct07707895","kind":"trial","name":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers","aka":[],"tldr":"A phase 1/2 trial of obrixtamig, ZL-1310 and atezolizumab in lung cancer, run by Boehringer Ingelheim, not yet recruiting.","summary":"DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers is a phase 1/2, interventional study registered as NCT07707895 by Boehringer Ingelheim, with a registry enrolment figure of 60 participants, started 2026-09-29 and due to reach its primary completion in 2030-04-26. Interventions recorded: Obrixtamig; ZL-1310; Atezolizumab. Conditions listed: Small Cell Lung Cancer; Large Cell Neuroendocrine Lung Carcinoma; Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology; Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology. Primary outcome: Part 1: The occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period; Part 2: The occurrence of treatment-emergent adverse events (AEs) leading to trial medication discontinuation or dose modification; Part 2: PFS rate at 6 months. Lung eligibility wording from the registry: \"* Small cell lung carcinoma (SCLC)\". Sites: Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain, United Kingdom, United States. United Kingdom sites listed: 2. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07707895","url":"https://clinicaltrials.gov/study/NCT07707895"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["obrixtamig","zl-1310","atezolizumab"],"companies":["boehringer-ingelheim"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Leicester Royal Infirmary (Leicester); Freeman Hospital (Newcastle upon Tyne)."],"nct":"NCT07707895","phase":"1/2","setting":"A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC","sponsor":"Boehringer Ingelheim","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07707895/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"obrixtamig","kind":"drug","name":"Obrixtamig","route":"/drugs/obrixtamig/"},{"id":"zl-1310","kind":"drug","name":"ZL-1310","route":"/drugs/zl-1310/"}],"company":[{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}